Adaptimmune Therapeutics plcAdaptimmune Therapeutics plcAdaptimmune Therapeutics plc

Adaptimmune Therapeutics plc

No trades
See on Supercharts

ADAP fundamentals

Adaptimmune Therapeutics plc financial statements, including revenue, expenses, profit, and loss

The total revenue of ADAP for the last quarter is 128.37 M USD, and it's 2162.21% higher compared to the previous quarter. The net income of Q2 24 is 69.60 M USD.

Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
‪0.00‬
Total revenue
Gross profit
Operating income
Pretax income
Net income
Currency: USD
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
TTM
Total revenueYoY growth
Gross profitYoY growth
Pretax incomeYoY growth
Net incomeYoY growth
EBITDAYoY growth
EBITYoY growth